Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.

OBJECTIVE:To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI). METHODS:A total of 240 patients were randomized to either a tirofiban group or a control group. RESULTS:Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1). CONCLUSIONS:The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.